Heraeus Pharmaceutical Ingredients’ has completed installation of an additional production line for Platinum-based highly potent active pharmaceutical ingredients (Pt HPAPIs) at the company’s headquarters in Hanau, Germany.
Work started on the production line in accordance with the latest EHS and GMP requirements in 2018, reportedly representing a multi-million Euro investment for Heraeus in response to increased demand for its products.
Successful validation of its production line means the company has significantly increased its manufacturing capacity.
“We are proud to have brought this project to a successful conclusion in such a short space of time. Our customers can now benefit from our additional capacity and quicker delivery times for top-quality active ingredients,” said Marcus Hannakam, Head of Pharmaceutical Ingredients at Heraeus.
“The global increase in demand for our active ingredients and the concentration on experienced, reliable manufacturers were key for our investment. This represents a major step toward long-term success, both for our customers and for Heraeus Pharmaceutical Ingredients.
“The expansion further secures the market leadership of Heraeus Pharmaceuticals Ingredients. As a long-established partner in the battle against cancer, the business line already enjoys an excellent reputation among customers and regulatory authorities which we intend to strengthen further with this latest investment.”
The Pt HPAPIs made at the are used to combat diseases such as lung cancer, colorectal cancer, ovarian cancer, and testicular cancer. The demand for the ingredients in cancer treatment is rising for various reasons, the company says, including demographic change and improving access to chemotherapies in emerging economies.
